Literature DB >> 8864530

Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists.

S M Candura1, E Messori, G P Franceschetti, G D'Agostino, D Vicini, M Tagliani, M Tonini.   

Abstract

1. In strips of human isolated detrusor muscle, the 5-hydroxytryptamine (5-HT) receptor (5-HT4) that mediates facilitation of neuromuscular cholinergic transmission was further characterized by using 5-HT and a series of ligands known for their 5-HT4 agonist (5-methoxytryptamine: 5-MeOT, cisapride, (R,S)-zacopride, BIMU 8) or antagonist (RS 23597, GR 125487, DAU 6285) properties. 2. In the presence of methysergide (1 microM) and ondansetron (3 microM) to isolate pharmacologically the 5-HT4 receptors, 5-HT (0.3 nM-1 microM), 5-MeOT (10 nM -30 microM), BIMU 8 (10 nM-3 microM), cisapride (0.1-10 microM) and (R,S)-zacopride (0.1-30 microM) potentiated cholinergic contractions to electrical field stimulation in a concentration-dependent manner. RS 23597 (10 nM-10 microM), a competitive 5-HT4 receptor antagonist in other systems, also showed agonist properties. The following rank order of potency as an agonist was obtained: 5-HT (pEC50 = 8.0) > RS 23597 (7.0) = BIMU 8 (6.9) > or = cisapride (6.6) > 5-MeOT (6.0) > or = (R,S)-zacopride (5.7). Relative to 5-HT (intrinsic activity = 1), 5-MeOT acted as a full agonist (1.03), while BIMU 8 (0.76), (R,S)-zacopride (0.61), RS 23597 (0.60) and cisapride (0.41) behaved as partial agonists. 3. The potentiation by 5-HT was competitively antagonized by the selective 5-HT4 receptor antagonist GR 125487 (0.3-3 nM) with a pA2 estimate of 9.75 (Schild slope of 1.09), and by DAU 6285 (1 microM; pK3 = 6.45). Additionally, GR 125487 (3 nM) antagonized the responses to 5-MeOT (pKB = 9.72) and reversed the potentiation induced by RS 23597. As an antagonist, RS 23597 (10, 30 and 100 nM) inhibited the response to 5-HT. In addition, 30 and 100 nM RS 23597 reduced the 5-HT response maximum by 30 and 50%, respectively. The pKB value calculated at 10 nM was 8.0. 4. Thus, in the human isolated detrusor muscle, the 5-HT4 receptors mediating facilitation of cholinergic neuromuscular transmission are activated by indoleamines (5-HT, 5-MeOT), substituted benzamide (cisapride, (R,S)-zacopride), benzoate (RS 23597) and benzimidazolone (BIMU 8) derivatives. The activities (in terms of both potency and efficacy) of most agonists, as well as the affinity estimates of the antagonists GR 125487 and DAU 6285, are comparable to those found in other peripheral tissues. Exceptions are RS 23597, which acted either as a partial agonist or as an antagonist of the response to 5-HT1 and 5-MeOT that showed an unusually low potency. The latter findings may be ascribed to differences in the efficiency of receptor coupling mechanisms and/or in the molecular structure (i.e. splice variants) of the 5-HT4 receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864530      PMCID: PMC1909897          DOI: 10.1111/j.1476-5381.1996.tb15631.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  DAU 6285: a novel antagonist at the putative 5-HT4 receptor.

Authors:  A Schiavone; E Giraldo; L Giudici; M Turconi; A Sagrada
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  Effects of cisapride on constipation due to a neurological lesion.

Authors:  G H de Groot; G F de Pagter
Journal:  Paraplegia       Date:  1988-06

3.  A study of human bladder detrusor muscle.

Authors:  J K Todd; A J Mack
Journal:  Br J Urol       Date:  1969-08

4.  Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig.

Authors:  J A Schuurkes; J M Van Nueten; P G Van Daele; A J Reyntjens; P A Janssen
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

5.  On the nature of the receptor mediating the action of 5-hydroxytryptamine in potentiating responses of the mouse urinary bladder strip to electrical stimulation.

Authors:  S E Holt; M Cooper; J H Wyllie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

6.  The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons.

Authors:  A Dumuis; M Sebben; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

7.  Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus.

Authors:  R Andrade; R A Nicoll
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

8.  Excitatory 5-hydroxytryptamine receptors in the cat urinary bladder are of the M- and 5-HT2-type.

Authors:  P R Saxena; J Heiligers; E J Mylecharane; R Tio
Journal:  J Auton Pharmacol       Date:  1985-06

9.  Treatment with cisapride of the gastrointestinal and urological sequelae of spinal cord transection: case report.

Authors:  M Etienne; M Verlinden; A Brassinne
Journal:  Paraplegia       Date:  1988-06

10.  Influence of serotonin on lower urinary tract smooth muscle in vitro.

Authors:  P Klarskov; J Hørby-Petersen
Journal:  Br J Urol       Date:  1986-10
View more
  9 in total

1.  An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle.

Authors:  N H Prins; N P Shankley; N J Welsh; M R Briejer; R A Lefebvre; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines.

Authors:  J Mialet; I Berque-Bestel; P Eftekhari; M Gastineau; M Giner; Y Dahmoune; P Donzeau-Gouge; J Hoebeke; M Langlois; S Sicsic; R Fischmeister; F Lezoualc'h
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

3.  Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites.

Authors:  M L López-Rodríguez; M J Morcillo; B Benhamú; M L Rosado
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

4.  5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle.

Authors:  N H Prins; L M Akkermans; R A Lefebvre; J A Schuurkes
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle.

Authors:  B Darblade; D Behr-Roussel; D Gorny; T Lebret; G Benoit; J-P Hieble; D Brooks; L Alexandre; F Giuliano
Journal:  World J Urol       Date:  2005-05-18       Impact factor: 4.226

6.  Underlying mechanism of the cyclic migrating motor complex in Suncus murinus: a change in gastrointestinal pH is the key regulator.

Authors:  Anupom Mondal; Kouhei Koyama; Takashi Mikami; Taichi Horita; Shota Takemi; Sachiko Tsuda; Ichiro Sakata; Takafumi Sakai
Journal:  Physiol Rep       Date:  2017-01

7.  Ketanserin and Naftopidil Enhance the Potentiating Effect of Alpha-Methyl-Serotonin on the Neurally-Induced Contraction of Human Isolated Urinary Bladder Muscle Strips.

Authors:  Tsuyoshi Hattori; Philippe Lluel; Céline Rouget; Moèz Rekik; Mitsuharu Yoshiyama
Journal:  Int Neurourol J       Date:  2017-03-24       Impact factor: 2.835

8.  Effect of single doses of citalopram and reboxetine on urethral pressure: A randomized, double-blind, placebo- and active-controlled three-period crossover study in healthy women.

Authors:  Thea Christoffersen; Jonatan Kornholt; Troels Riis; Jesper Sonne; David P Sonne; Niels Klarskov
Journal:  Neurourol Urodyn       Date:  2022-06-30       Impact factor: 2.367

9.  Activation of uroepithelial 5-HT4R inhibits mechanosensory activity of murine bladder afferent nerves.

Authors:  Yu Lu; Jie Li; Li Dong; Ping Luo; Guohua Zhang; Weifang Rong
Journal:  Front Physiol       Date:  2022-09-13       Impact factor: 4.755

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.